KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Change in Accured Expenses (2016 - 2019)

Thermo Fisher Scientific (TMO) has disclosed Change in Accured Expenses for 11 consecutive years, with $38.0 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Change in Accured Expenses fell 75.8% year-over-year to $38.0 million, compared with a TTM value of $210.0 million through Dec 2019, up 600.0%, and an annual FY2019 reading of $210.0 million, up 600.0% over the prior year.
  • Change in Accured Expenses was $38.0 million for Q4 2019 at Thermo Fisher Scientific, up from -$147.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $992.0 million in Q4 2017 and bottomed at -$471.0 million in Q1 2018.
  • Average Change in Accured Expenses over 5 years is $80.0 million, with a median of $115.2 million recorded in 2015.
  • Peak annual rise in Change in Accured Expenses hit 12019.44% in 2015, while the deepest fall reached 247.98% in 2015.
  • Year by year, Change in Accured Expenses stood at $436.3 million in 2015, then decreased by 16.89% to $362.6 million in 2016, then surged by 173.58% to $992.0 million in 2017, then tumbled by 84.17% to $157.0 million in 2018, then plummeted by 75.8% to $38.0 million in 2019.
  • Business Quant data shows Change in Accured Expenses for TMO at $38.0 million in Q4 2019, -$147.0 million in Q3 2019, and $549.0 million in Q2 2019.